Obesity, overweight and related conditions: define your treatment goal

One body size does not describe your whole health

NIDDK describes associations between overweight or obesity and conditions such as type 2 diabetes, cardiovascular disease and sleep apnea. An association does not mean that every person has every condition. Your history, symptoms, examination and tests are the basis for your own assessment.

The WHO GLP-1 questions and answers emphasizes clinical assessment and broader care. You deserve respectful support at any size. Treatment goals can include daily function and quality of life as well as measures your clinician considers relevant. A weight graph alone cannot diagnose disease or establish that it has resolved.

Keep the indication specific

These examples describe United States approvals, not automatic eligibility in another country. They are not an exhaustive list. Your clinician should check the current local product information.

• Type 2 diabetes: MedlinePlus distinguishes products used for diabetes from products used for obesity. Sharing an ingredient does not make brands or presentations interchangeable.
• Obstructive sleep apnea: the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity. This does not mean every GLP-1 product treats every sleep problem, or that an app replaces a sleep study.
• Cardiovascular disease: the FDA approved a Wegovy indication for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. That is more specific than “protects everyone's heart.”

Current Wegovy and Zepbound labels provide the product details. Do not stop diabetes, blood-pressure or sleep-apnea treatment because weight changes.

Build a one-page care conversation

• Reason for treatment: write the goal as your prescriber explained it. Keep “diagnosed,” “being assessed” and “a question I have” separate.
• Current care: list medicine names, relevant specialists, devices used under your care plan and the next appointment. Preserve existing medical instructions.
• Your priorities: choose a daily-life concern such as tiredness, mobility, sleep or worry about starting. A personal priority does not need a numerical score.
• Follow-up: ask which results will be reviewed, who orders them and how you will discuss tolerability. A reminder is not evidence that a clinical review occurred.

Start with the free appointment preparation tool. Keep laboratory and device reports in their original form when your clinician requests them.

Ask what success and safety mean for you

“What condition are we treating?” “How will we judge benefit beyond weight?” “Which symptoms need earlier contact?” “Who coordinates my different prescriptions?” If new severe chest pain, breathing difficulty or loss of consciousness occurs, seek emergency help instead of waiting for a planned review.

Frequently asked questions

Does overweight automatically qualify me for GLP-1?

No. Eligibility depends on the particular product, local rules, clinical assessment and your circumstances. A website cannot establish it.

Can better sleep prove my apnea is gone?

No. Discuss symptom changes with your sleep team. Do not independently discontinue prescribed apnea treatment.

Will Capydose coordinate my medical care?

You control the record and decide whether to share a report. The app is not connected to your clinicians and does not arrange or replace reviews.

A record you can bring to your appointment

A record of symptoms, energy and questions keeps your own priorities visible alongside any weight entries. Capydose keeps dose, symptom and wellbeing entries together, with PDF or CSV exports you choose to share. Its capybara is a friendly visual companion for your routine. It does not detect complications or provide live medical care.

Explore Capydose for iPhone or start with the free wellbeing journal. In-app tracking requires Premium after onboarding and iOS 18 or later. Android remains in review.